- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00261547
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A long established risk factor for late renal allograft loss is the development of DSA. Recent studies from our group and others have shown that these antibodies are probably responsible for chronic rejection by attacking the vascular endothelium and fixing complement (detected as C4d in renal biopsies). Studies in humans and monkeys have shown that circulating antibody and complement deposition precede the development of chronic graft injury. Interruption of antibody production is a potential beneficial strategy to prevent late graft loss from this mechanism.
Therapeutic regimens that have been used in an attempt to deplete HLA or ABO antibodies include plasmapheresis, IVIg, tacrolimus and mycophenolate mofetil (MMF), and anti-CD20 (rituximab). Of these regimens, the most specific is anti-CD20, rituximab (rituxan), a therapy now FDA approved for B cell proliferative diseases. Although initially introduced for the treatment of neoplasm, the humoral immunosuppressant effects of rituximab have been shown to have clinical significance. Rituximab interferes with both primary and secondary humoral responses by eliminating B-cells prior to antigen exposure, thus interfering with differentiation into antibody secreting cells and specific antibody production.
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recipient of a primary cadaver or living donor renal allograft
- 18-64 years of age
- At least 6 months and no more than 10 years post renal transplant
- Serum clearly positive for defined DSA
- Renal biopsy positive for C4d staining within 28 days before study Day 1 treatment
- Blood positive for Cd 19/20 cells at greater than/equal to 50 % of lower limit of normal
- Baseline serum creatinine 1.7-3.0 mg/dl
- On stable doses of tacrolimus and MMF for at least 1 month prior to study entry
- Able and willing to sign IRB approved consent form and comply with the requirements of the screen, treatment and follow-up phase of the protocol
- Negative serum pregnancy test (women of child bearing potential)
- Men and women of reproductive potential agree to use an acceptable method of birth control during treatment, for twelve months after treatment completion, or until B cell counts return to normal, whichever is longer
Exclusion Criteria:
- Hemoglobin: < 8.5 gm/dL
- Platelets: < 100.00/mm
- White blood cell count: < 3000/mm3
- AST or ALT . 2.5 x Upper Limit of Normal unless related to primary disease
- Positive Hepatitis B or C serology
- History of positive HIV
- Treatment with any investigational agen within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)
- Receipt of a live vaccine within 4 weeks prior to study entry
- Previous treatment with rituximab (rituxan)
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of recurrent infections
- Known active bacterial, viral, fungal, mycobacterial or other infection or any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
- Ongoing use of high dose steroids (>10mg/day) or unstable steroid dose in the past 4 weeks.
- Lack of peripheral venous access
- History of drug, alcohol or chemical abuse within 6 months prior to screen
- Pregnancy or lactation
- Concomitant malignancies or previous malignancies
- History of psychiatric disorder that would interfere with normal participation in this protocol
- Significant cardiac or pulmonary disease
- Any other disease, metabolic dysfunction, physical examination finding or clinical lab finding giving reasonable suspicion of disease or condition that contraindicates use of an investigational drug or that may affect the interpretation of the results or render subject a high rist from treatment complications
- Inability to comply with study and follow-up procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab
this study has only one arm as the treatment group
|
All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Negative DSA by Luminex beads or ELISA
Time Frame: at 12 months post study medication
|
at 12 months post study medication
|
Lack of C4d deposition in peritubular capillary
Time Frame: on 12 month renal biopsy
|
on 12 month renal biopsy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Renal allograft function: Serum creatinine, Calculated creatinine clearance, Urine protein, Urine protein-creatinine ratio
Time Frame: 12 months after study entry compared to the baseline
|
12 months after study entry compared to the baseline
|
Change in chronic rejection pathology indices
Time Frame: on 12-month renal biopsy compared to baseline biopsy.
|
on 12-month renal biopsy compared to baseline biopsy.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nina Tolkoff-Rubin, M.D., Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Renal Insufficiency
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- 2005p001524
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Insufficiency
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
CHU de ReimsInstitut National de la Santé Et de la Recherche Médicale, FranceUnknownKidney Transplantation | Chronic Kidney InsufficiencyFrance
-
B.Braun Avitum AGWinicker Norimed GmbHCompletedRenal Insufficiency,Chronic | Kidney Insufficiency | Kidney Disease, End-Stage | Kidney Failure,ChronicCzech Republic
-
SandozCompletedChronic Kidney InsufficiencyAustria
-
China Medical University HospitalMinistry of Health and Welfare, TaiwanUnknownChronic Kidney Diseases | Chronic Kidney InsufficiencyTaiwan
-
University of AarhusCompletedHypertension | Vasodilation | Chronic Kidney InsufficiencyDenmark
-
CHU de ReimsRecruitingChronic Kidney InsufficienciesFrance
-
University Hospital TuebingenWithdrawnAcute Kidney Insufficiency | Anti-Infective Agent ToxicityGermany
-
Corporacion Parc TauliUnknownChronic Kidney Insufficiency | Hemodialysis Treatment | Diuresis PreservedSpain
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States